Autolus Therapeutics Future Growth
Future criteria checks 2/6
Autolus Therapeutics is forecast to grow earnings and revenue by 50% and 59% per annum respectively. EPS is expected to grow by 52.4% per annum. Return on equity is forecast to be -311.9% in 3 years.
Key information
50.0%
Earnings growth rate
52.4%
EPS growth rate
Biotechs earnings growth | 27.6% |
Revenue growth rate | 59.0% |
Future return on equity | -311.9% |
Analyst coverage | Good |
Last updated | 10 Dec 2024 |
Recent future growth updates
Recent updates
AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market
Nov 21Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case
Sep 06Is Autolus Therapeutics (NASDAQ:AUTL) Using Debt Sensibly?
Aug 15Autolus Therapeutics: Major Inflection Point On The Horizon
Jul 31Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity
May 14We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely
Nov 06Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation
Jun 26We Think Autolus Therapeutics (NASDAQ:AUTL) Can Afford To Drive Business Growth
Mar 09Is Autolus Therapeutics plc (NASDAQ:AUTL) Worth US$1.9 Based On Its Intrinsic Value?
Dec 12Autolus stock rises as Moderna uses option to license targeting technology for mRNA therapy
Oct 12Autolus Therapeutics: Overlooked CAR-T Player With Key Catalysts Approaching
Aug 17Autolus Therapeutics Q2 2022 Earnings Preview
Aug 03Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation
Apr 19Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 147 | -129 | -91 | -73 | 6 |
12/31/2025 | 58 | -201 | -150 | -126 | 8 |
12/31/2024 | 17 | -223 | -208 | -182 | 8 |
9/30/2024 | 10 | -270 | -206 | -193 | N/A |
6/30/2024 | 10 | -234 | -161 | -157 | N/A |
3/31/2024 | 10 | -221 | -152 | -144 | N/A |
12/31/2023 | 2 | -208 | -157 | -146 | N/A |
9/30/2023 | 6 | -158 | -145 | -135 | N/A |
6/30/2023 | 7 | -155 | -142 | -127 | N/A |
3/31/2023 | 7 | -152 | -133 | -120 | N/A |
12/31/2022 | 6 | -149 | -123 | -112 | N/A |
9/30/2022 | 3 | -164 | -119 | -107 | N/A |
6/30/2022 | 1 | -155 | -119 | -110 | N/A |
3/31/2022 | 2 | -146 | -123 | -116 | N/A |
12/31/2021 | 2 | -142 | -127 | -118 | N/A |
9/30/2021 | 3 | -143 | -149 | -136 | N/A |
6/30/2021 | 3 | -147 | -154 | -141 | N/A |
3/31/2021 | 2 | -145 | -145 | -131 | N/A |
12/31/2020 | 2 | -142 | -132 | -118 | N/A |
9/30/2020 | 2 | -140 | -134 | -123 | N/A |
6/30/2020 | 1 | -130 | -120 | -109 | N/A |
3/31/2020 | 1 | -127 | -113 | -99 | N/A |
12/31/2019 | 3 | -124 | -120 | -101 | N/A |
9/30/2019 | 3 | -104 | -109 | -88 | N/A |
6/30/2019 | 3 | -89 | -93 | -72 | N/A |
3/31/2019 | 3 | -68 | -76 | -61 | N/A |
12/31/2018 | 1 | -58 | -56 | -43 | N/A |
9/30/2018 | 1 | -45 | -41 | -32 | N/A |
6/30/2018 | 1 | -41 | N/A | N/A | N/A |
3/31/2018 | 2 | -38 | N/A | N/A | N/A |
12/31/2017 | 2 | -29 | N/A | N/A | N/A |
9/30/2017 | 2 | -20 | N/A | -16 | N/A |
9/30/2016 | 1 | -13 | N/A | -10 | N/A |
9/30/2015 | 0 | -7 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AUTL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AUTL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AUTL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AUTL's revenue (59% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: AUTL's revenue (59% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AUTL is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 09:18 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Autolus Therapeutics plc is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Ingrid Gafanhão | Bryan Garnier & Co |
Rajan Sharma | Goldman Sachs |
Debjit Chattopadhyay | H.C. Wainwright & Co. |